| Liu, Yang |
NCT05694585: Effect of Esmolol on Perioperative Stress Reaction |
|
|
| Not yet recruiting | 4 | 46 | NA | Esmolol, Esmolol hydrochloride, saline, 0.9% sodium chloride injection solution | Xiumei Song | Esmolol, Stress Reaction, Airway Obstruction, Catecholamine; Overproduction | 12/23 | 12/23 | | |
NCT03989336: A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT06404840: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | nimotuzumab, AG chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 03/25 | 05/26 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
|
|
| Recruiting | 2 | 200 | RoW | Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab | Chinese PLA General Hospital | Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | 08/22 | 08/25 | | |
NCT06586697: First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy |
|
|
| Recruiting | 2 | 47 | RoW | Thoracic Radiotherapy | Henan Cancer Hospital | Extensive-stage Small-cell Lung Cancer | 01/26 | 03/26 | | |
CHN-PLAGH-BT-045, NCT04233294: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide, Camrelizumab, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 02/24 | 02/26 | | |
NCT06375486: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. |
|
|
| Recruiting | 2 | 30 | RoW | Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, HAIC | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma | 03/25 | 06/26 | | |
OBU-HCC-II-001, NCT06405061: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Adebrelimab, Bevacizumab, HAIC | Tianjin Medical University Cancer Institute and Hospital | Adebrelimab, Hepatocellular Carcinoma | 05/25 | 08/27 | | |
NCT06342466: Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis |
|
|
| Recruiting | 2 | 40 | RoW | Bortezomib, Velcade, Pomalidomide, Dexamethasone | Jin Lu, MD | Systemic Amyloidosis | 12/26 | 12/26 | | |
NCT06418477: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD |
|
|
| Recruiting | 2 | 20 | RoW | Dara-CyBorD | Peking University People's Hospital | Monoclonal Gammopathy of Renal Significance | 12/25 | 12/26 | | |
NCT06558773: GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. |
|
|
| Not yet recruiting | 2 | 120 | RoW | Eliglustat+Immune checkpoint inhibitor+Regorafenib, Regorafenib(Stivarga), Eliglustat(Cerdelga), Eliglustat+Immune checkpoint inhibitor, Regorafenib+Immune checkpoint inhibitor | Chinese PLA General Hospital | Colorectal Cancer | 08/26 | 08/27 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT04553393: Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden |
|
|
| Recruiting | 1/2 | 80 | RoW | Chidamide, cohort 2, Decitabine, cohort 3, Chidamide and Decitabine, cohort 4, Decitabine-primed Tandem CAR19/20 engineered T cells, cohort 1 | Chinese PLA General Hospital | Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden | 09/21 | 09/22 | | |
NCT04588324: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 50 | RoW | SHR2150, Anti-Cancer Agent | Chinese PLA General Hospital | Solid Tumor | 11/21 | 11/22 | | |
NCT04897477: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | Azacytidine, Bendamustine and Piamprizumab | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 04/22 | 04/23 | | |
NCT04873440: An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 10 | RoW | Manganese Chloride, Mn2+, Radiotherapy, Chemo-immunotherapy | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 05/22 | 05/23 | | |
NCT04697940: Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL |
|
|
| Recruiting | 1/2 | 33 | RoW | Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Han weidong | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells | 12/24 | 12/25 | | |
NCT06321289: Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogeneic CD19-STAR T cell, Allogeneic CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 03/26 | 03/27 | | |
NCT04337606: Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, Decitabine, Camrelizumab | Chinese PLA General Hospital | Non Hodgkin Lymphoma | 04/24 | 04/26 | | |
NCT06323525: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma | 04/26 | 04/27 | | |
NCT05631912: TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 38 | RoW | Autologous CD19-STAR-T cell, Autologous CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 12/24 | 12/25 | | |
NCT05554939: Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogenic CD19-CAR-γδT cell, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 12/25 | 12/26 | | |
NCT06481735: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Allogeneic Power3 knock-out CD19 CAR-T, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital, Peking University | Acute Lymphocytic Leukemia | 02/27 | 02/28 | | |
NCT03381807: Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion |
|
|
| Recruiting | 1 | 20 | RoW | hAESCs | Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | Intrauterine Adhesion | 09/22 | 09/23 | | |
NCT05438394: Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM |
|
|
| Recruiting | 1 | 24 | RoW | melphalan hydrochloride for injection | Peking University People's Hospital, CASI Pharmaceuticals, Inc. | Multiple Myeloma | 12/23 | 12/23 | | |
AK104-IIT-C-N1-0042, NCT05856864: Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy |
|
|
| Recruiting | 1 | 30 | RoW | Cadonilimab Injection, AK104, Ramucirumab Injection | Tianjin Medical University Cancer Institute and Hospital | Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | 07/24 | 05/25 | | |
NCT06464965: Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | RoW | CB CAR-NK182 | Zhejiang Provincial People's Hospital, Zhejiang University, Hangzhou RongGu Biotechnology Limited Company | Gastric Cancer, Pancreas Adenocarcinoma | 06/25 | 06/27 | | |
NCT06528249: Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies |
|
|
| Not yet recruiting | 1 | 39 | NA | Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes | Zhejiang Provincial People's Hospital, Westlake Therapeutics | Cancer, Solid Tumor, Hematologic Malignancy | 07/26 | 12/26 | | |
NCT04810910: Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy |
|
|
| Recruiting | 1 | 20 | RoW | iNeo-Vac-P01, Neoantigen peptides, GM-CSF, immune adjuvant, granulocyte-macrophage colony stimulating factor | Zhejiang Provincial People's Hospital, Hangzhou Neoantigen Therapeutics Co., Ltd. | Resectable Pancreatic Cancer | 03/25 | 03/25 | | |
NCT05631899: CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 15 | RoW | KRAS-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, Anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab | Chinese PLA General Hospital, Zhejiang University | Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C, KRAS G12D | 12/25 | 12/26 | | |
NCT03809390: Effects of Vaginal Seeding on Infants' Body Mass Index and Allergy Risk for Caesarean-delivered Children |
|
|
| Active, not recruiting | N/A | 117 | RoW | Vaginal seeding | Peking University, National Natural Science Foundation of China, Liuyang Maternal and Child Health Care Hospital | Overweight and Obesity, Allergy | 09/21 | 11/22 | | |
NCT05333497: Programmed Flexor-extensor Alternating Electrical Acupiont Stimulation on Limb Functional Reconstruction After Stroke |
|
|
| Completed | N/A | 84 | RoW | the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument, the fourth generation of low-frequency acupoint electric stimulation therapy instrument, patent No. : ZL201610793646.9 | Yang Liu | Stroke Sequelae, Movement Disorders | 04/22 | 02/23 | | |
NCT05735054: A Novel Technique for Endoscopic Transaxillary Thyroidectomy Comparison |
|
|
| Active, not recruiting | N/A | 300 | RoW | endoscopic thyroidectomy | Second Affiliated Hospital of Xi'an Jiaotong University | Thyroid Diseases | 12/22 | 12/24 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
| Recruiting | N/A | 714 | RoW | ERA | Peking University Third Hospital, RenJi Hospital, Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Infertility, Female, IVF/ICSI | 03/23 | 04/23 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT06286631: Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale |
|
|
| Recruiting | N/A | 800 | RoW | | Second Affiliated Hospital of Xi'an Jiaotong University | Papillary Thyroid Cancer | 10/25 | 10/26 | | |
NCT06192979: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
|
|
| Recruiting | N/A | 41 | RoW | Daratumumab, Bortezomib, Dexamethasone, Venetoclax | Jin Lu, MD | Amyloidosis; Systemic, AL Amyloidosis | 12/25 | 06/26 | | |
NCT06448897: Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques. |
|
|
| Recruiting | N/A | 4000 | RoW | | Obstetrics & Gynecology Hospital of Fudan University | Cervical Cancer, Lymph Node Metastasis, Artificial Intelligence | 12/25 | 12/25 | | |
NCT06423547: Risk Warning Model of Postoperative Delirium and Long-term Cognitive Dysfunction in Elderly Patients |
|
|
| Not yet recruiting | N/A | 10000 | NA | no intervention | Xuanwu Hospital, Beijing, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences | Postoperative Delirium, Postoperative Neurocognitive Disorder, Surgery | 12/27 | 12/27 | | |
NCT06369935: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. |
|
|
| Not yet recruiting | N/A | 260 | RoW | Equecabtagene Autoleucel, CT103A | Peking University People's Hospital | Relapsed/Refractory Multiple Myeloma | 08/26 | 08/27 | | |
NCT06699394: Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis |
|
|
| Recruiting | N/A | 20 | RoW | Teclistamab (Tec) | Peking University People's Hospital | AL Amyloidosis | 12/25 | 12/26 | | |
NCT06697483: Risk Stratification and MRD-driven Maintenance for MM After ASCT |
|
|
| Recruiting | N/A | 100 | RoW | Daratumumab, Lenalidomide | Peking University People's Hospital | Multiple Myeloma | 12/26 | 12/27 | | |
| Recruiting | N/A | 2000 | RoW | AI-assisted medical decision support system | The Eye Hospital of Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, ZhuHai Hospital, Macau University of Science and Technology Hospital | Ocular Diseases | 12/26 | 12/26 | | |
NCT06755190: Ophthalmic Multimodal AI-Assisted Medical Decision-Making |
|
|
| Recruiting | N/A | 5000000 | RoW | Diagnostic Test: AI-Based Diagnostic and Prognostic Model for Ocular Diseases | The Eye Hospital of Wenzhou Medical University | Ocular Diseases | 02/25 | 03/25 | | |
HODMChina, NCT05583058: Sex Hormone Overdose and Misuse in Chinese Transgender and Gender Non-conforming Population |
|
|
| Not yet recruiting | N/A | 260 | RoW | Hormone Overdose and Misuse | Xiamen University, Tongji University, Tsinghua University | Gender Incongruence, Gender Dysphoria | 06/28 | 03/29 | | |
| Wang, Haiyun |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
| Cui, Zilin |
OBU-HCC-II-001, NCT06405061: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Adebrelimab, Bevacizumab, HAIC | Tianjin Medical University Cancer Institute and Hospital | Adebrelimab, Hepatocellular Carcinoma | 05/25 | 08/27 | | |
